Meloxicam is generally considered one of the safer prescription NSAIDs, but it still carries real risks, particularly for your stomach, heart, and kidneys. It belongs to a class of anti-inflammatory drugs that preferentially targets the enzyme involved in inflammation while relatively sparing the one that protects your stomach lining. That selectivity gives it a modest safety edge over older NSAIDs like ibuprofen or naproxen for digestive side effects, though it doesn’t eliminate them.
How Meloxicam Compares to Other NSAIDs
All NSAIDs work by blocking enzymes called COX-1 and COX-2. COX-2 drives inflammation and pain. COX-1 helps maintain the protective lining of your stomach and supports normal kidney and platelet function. Older NSAIDs block both roughly equally, which is why stomach problems are so common with them.
Meloxicam is classified as a relatively selective COX-2 inhibitor, meaning it preferentially blocks the inflammation enzyme while doing less damage to your stomach’s defenses. It sits in a middle ground: more selective than ibuprofen or naproxen, but less selective than drugs like celecoxib, which was designed specifically as a COX-2 inhibitor. This partial selectivity is the main reason meloxicam has a reputation as a gentler option on the gut.
Stomach and Digestive Risks
Digestive side effects are the most common problem with meloxicam. In clinical trials involving over 10,000 osteoarthritis patients, gastrointestinal complaints occurred in about 17% of people taking the lower 7.5 mg dose and 20% at the higher 15 mg dose over 12 weeks. These were mostly mild issues: indigestion, diarrhea, nausea, and gas. Over six months, those rates climbed to roughly 25% at either dose, reflecting the cumulative effect on the stomach lining.
Serious complications like stomach ulcers, bleeding, or perforation are far less common. A pooled analysis of 35 trials covering over 27,000 patients found only 54 clinically significant upper gastrointestinal events. In an 18-month study of 357 rheumatoid arthritis patients taking the higher 15 mg dose daily, serious GI events (perforation, ulcer, or bleeding) occurred in just 0.8% of patients. That’s a low rate, but not zero, and the risk is dose-dependent. Staying at 7.5 mg when it controls your symptoms meaningfully reduces your exposure.
Cardiovascular Concerns
Meloxicam carries an FDA black box warning, the most serious type, for cardiovascular risk. All NSAIDs (except aspirin) can increase your chances of heart attack, stroke, and blood clots, and this risk grows the longer you take them. The warning is not unique to meloxicam; it applies to every prescription NSAID on the market.
People with existing heart disease or risk factors like high blood pressure, high cholesterol, diabetes, or smoking face a higher baseline risk that NSAIDs can amplify. Meloxicam is also specifically contraindicated after coronary artery bypass surgery. For people without cardiovascular risk factors using it short-term, the absolute increase in heart attack or stroke risk is small, but it’s not negligible over months or years of daily use.
Kidney Effects
Your kidneys rely on the same enzymes that meloxicam blocks to maintain normal blood flow. This means meloxicam can reduce kidney function, especially in people who are already vulnerable: older adults, anyone who is dehydrated, and people with pre-existing kidney disease.
Meloxicam is contraindicated if your kidney filtration rate (creatinine clearance) falls below 30 mL/min, which indicates severe impairment. For people on dialysis with severe kidney failure, the dose is capped at 7.5 mg daily. If you have mild or moderate kidney impairment, no dose adjustment is required, but your kidney function should be monitored, particularly in the first couple of weeks.
The Dose Makes a Difference
Meloxicam is prescribed at either 7.5 mg or 15 mg once daily. The difference in side effect rates between these two doses is consistent across trials and worth understanding if you’re weighing your options.
In 12-week osteoarthritis trials, overall GI side effects affected 17.2% at 7.5 mg versus 20.1% at 15 mg. Diarrhea showed a particularly clear dose relationship: 3.8% at the lower dose and 7.8% at the higher one. In rheumatoid arthritis trials, the gap was similar, with GI complaints in 14.1% at 7.5 mg versus 18.9% at 15 mg. Nausea also trended higher at the 15 mg dose across multiple studies, reaching 7.2% in a six-month osteoarthritis trial compared to 4.7% at 7.5 mg.
The practical takeaway: if 7.5 mg controls your pain adequately, there’s a measurable safety advantage to staying at that dose rather than doubling it.
Drug Combinations That Raise Risk
Several common medications interact with meloxicam in ways that increase the chance of bleeding or kidney damage.
- Blood thinners (warfarin and similar drugs): Meloxicam and anticoagulants have a synergistic effect on bleeding, meaning the combined risk is greater than either drug alone.
- Antidepressants (SSRIs and SNRIs): These affect serotonin, which plays a role in blood clotting. Taking them alongside meloxicam raises bleeding risk beyond what the NSAID causes on its own.
- Low-dose aspirin: Combining meloxicam with aspirin, even at the low doses used for heart protection, increases GI bleeding risk and is generally not recommended.
- Blood pressure medications (ACE inhibitors, ARBs, diuretics): These combinations can impair kidney function, particularly in older adults or anyone who is volume-depleted. Diuretics can also become less effective.
- Other NSAIDs: Stacking meloxicam with ibuprofen, naproxen, or other anti-inflammatories compounds GI toxicity without adding proportional pain relief.
Long-Term Use: What 18 Months of Data Shows
An 18-month study of 357 rheumatoid arthritis patients taking meloxicam 15 mg daily provides some of the longest safety data available. Nearly 70% of patients experienced at least one adverse event over the full treatment period, which sounds alarming but includes every complaint from mild headaches to skin rashes. The most relevant findings: 27.7% reported GI side effects of any severity, 3.9% withdrew specifically because of GI problems, and only 0.8% experienced serious GI complications like ulcers or bleeding. Overall, 13.7% of patients discontinued due to side effects of any kind.
These numbers suggest that most people tolerate meloxicam reasonably well over extended periods, but roughly one in seven finds the side effects bothersome enough to stop. The GI tract remains the primary concern even with meloxicam’s relative stomach-sparing properties, and the longer you take it, the more cumulative exposure your stomach lining absorbs.
Pregnancy Risks
The FDA warns against using meloxicam (or any NSAID) from 20 weeks of pregnancy onward. After that point, the baby’s kidneys produce most of the amniotic fluid, and NSAIDs can impair fetal kidney function enough to reduce amniotic fluid levels. That fluid cushions the baby and is essential for lung, digestive, and muscle development. After 30 weeks, NSAIDs should be avoided entirely. Before 20 weeks, the risks are less defined, but use should still be limited to the lowest effective dose for the shortest possible time.
Monitoring While Taking Meloxicam
If you’re using meloxicam regularly, periodic blood work helps catch problems before they become serious. Before starting, baseline kidney function, a complete blood count, and liver enzymes (if you have liver issues) establish your starting point. Within two weeks of starting or changing your dose, kidney function and blood counts should be rechecked. Once you’re stable, periodic monitoring continues, with the frequency depending on your risk factors. People taking blood pressure medications alongside meloxicam or those with any degree of kidney impairment need closer attention to kidney function over time.